Treatment of infantile hemangiomas with beta-blockers: a review.
Infantile hemangiomas (IH) are the most common tumors occurring in early childhood, with a prevalence of approximately 5-10% of infants. While the natural history of IH is to spontaneously involute, a significant minority of IH require therapy with the aim to prevent disfigurement, functional impairment, or ulceration. In 2008, propranolol, a non-selective beta (β)-blocker, was reported to be highly effective in treating IH. Since that time there have been more than 200 articles published regarding the efficacy and potential toxicity of β-blockers, both systemic and topical, for the treatment of IH. Based on these finding, β-blockers appear to be highly effective in treating IH and are well tolerated, though side effects have been reported. When therapy is appropriately monitored, β-blockers have been proven to be a safer and superior alternative to systemic steroids.